Document Detail

An overview of the pharmacology and clinical efficacy of indapamide sustained release.
MedLine Citation:
PMID:  16313275     Owner:  NLM     Status:  MEDLINE    
The relationship between blood pressure (BP) and cardiovascular risk is clearly established; hypertension increases the rate of cardiovascular. High systolic blood pressure (SBP) may be the main parameter involved in cardiovascular morbidity and mortality. The benefit of lowering BP, particularly with diuretics has been proven in many outcome studies. Indapamide, a thiazide-type diuretic, was available for many years at a dosage of 2.5 mg in an immediate release formulation. A new sustained release (SR) formulation has been developed in order to allow the same antihypertensive efficacy with a better acceptability profile. This paper reviews the pharmacology of indapamide 1.5 mg SR from the bench to the bedside. Indapamide has a dual mechanism of action: diuretic effect at the level of the distal tubule in the kidney and a direct vascular effect, both of which contribute to the antihypertensive efficacy of the drug. The SR formulation contains a hydrophilic matrix, which delivers a smoother pharmacokinetic profile. This avoids unnecessary plasma peak concentrations, which may be associated with side effects. Indapamide SR has now been extensively used in hypertensive patients, including those at increased risk, for example elderly or diabetic patients. It has been shown to decrease BP, particularly SBP, with 24-h efficacy, allowing a once-daily dosage. Studies have demonstrated BP lowering to be at least as effective as all major therapeutic classes including the more recent antihypertensive drugs. Beyond BP decrease, indapamide SR has also been shown to protect against hypertensive target-organ damage in the heart and the kidney and to have a favorable metabolic profile. A broad evidence-base has accumulated to support the benefit of indapamide 1.5 mg SR in hypertensive patients, alone or as part of combination therapy, as recommended by the majority of guidelines.
J Sassard; A Bataillard; H McIntyre
Related Documents :
7365955 - Prevention and control of hypertension by nutritional-hygienic means. long-term experie...
18426375 - Identifying barriers to hypertension care: implications for quality improvement initiat...
20134405 - Effects of korean red ginseng (panax ginseng c.a. mayer) and its isolated ginsenosides ...
6085365 - Efficacy of nitrendipine as baseline antihypertensive therapy.
11713895 - The elderly hypertensive; cardiovascular and neurohormonal profile.
7090725 - The use of labetalol in producing deliberate hypotension and its effects on intracrania...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Fundamental & clinical pharmacology     Volume:  19     ISSN:  0767-3981     ISO Abbreviation:  Fundam Clin Pharmacol     Publication Date:  2005 Dec 
Date Detail:
Created Date:  2005-11-29     Completed Date:  2006-03-28     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8710411     Medline TA:  Fundam Clin Pharmacol     Country:  England    
Other Details:
Languages:  eng     Pagination:  637-45     Citation Subset:  IM    
Département de Physiologie et Pharmacologie Clinique, Faculté de Pharmacie, 8, avenue Rockefeller, 69373 - Lyon Cedex 08, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Albuminuria / complications,  drug therapy
Antihypertensive Agents / administration & dosage,  blood,  pharmacology*,  therapeutic use*
Delayed-Action Preparations
Diabetes Mellitus, Type 2 / complications
Evidence-Based Medicine
Hypertrophy, Left Ventricular / drug therapy
Indapamide / administration & dosage,  blood,  pharmacology*,  therapeutic use*
Practice Guidelines as Topic
Reg. No./Substance:
0/Antihypertensive Agents; 0/Delayed-Action Preparations; 26807-65-8/Indapamide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The influence of weightlessness on pharmacokinetics.
Next Document:  Pharmacological interventions that directly stimulate or modulate insulin secretion from pancreatic ...